Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242161 | 0.78 | P2RY1 (0.39) | P2RY1KDM4EALDH1A1POLBPLCG1 | |
| SCHEMBL17700421 | 0.76 | NAPRT (0.38) | P2RY1KDM4EALDH1A1POLBNAPRT | |
| SCHEMBL27853505 | 0.75 | KDM4E (0.40) | KDM4EALDH1A1NAPRTMYCTDP1 | |
| SCHEMBL14803694 | 0.75 | ALDH1A1 (0.38) | P2RY1KDM4EALDH1A1PLCG1RBP4 | |
| SCHEMBL14803892 | 0.73 | KDM4E (0.38) | P2RY1KDM4EALDH1A1POLBPLCG1 | |
| SCHEMBL5241823 | 0.70 | KDM4E (0.55) | P2RY1KDM4EALDH1A1PLCG1NAPRT | |
| SCHEMBL14803695 | 0.70 | METAP2 (0.39) | P2RY1KDM4EALDH1A1RBP4 | |
| SCHEMBL27853494 | 0.70 | GABRP (0.40) | KDM4EALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL3242526 | 0.69 | KDM4E (0.53) | P2RY1KDM4EALDH1A1PLCG1NAPRT | |
| SCHEMBL1834470 | 0.69 | ALDH1A1 (0.41) | P2RY1KDM4EALDH1A1PLCG1MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | P2RY1 1749/4885KDM4E 918/4885ALDH1A1 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.